The most-watched episode of The Joe Rogan Experience podcast to date is episode 1169, featuring Tesla CEO Elon Musk. This episode in particular attracted widespread attention, not only because viewers were eager to hear the serial entrepreneur talk about his latest venture, but also because Musk did something very unusual for a tech billionaire— —He smoked marijuana on camera.
Indeed, Musk’s 2018 live broadcast quickly made headlines across a variety of news outlets, from CNN to the BBC to Fox Business, in addition to sparking a slew of memes on social media platforms.
do not miss it
However, this stunt This is not without consequences for Musk, who is currently the world’s richest man with a net worth of $204.1 billion.
In a 2022 interview on the “Full Send” podcast, Musk shared the aftermath of his appearance on the Joe Rogan Experience, reveal“, “This is actually not good for me and SpaceX, because [weed] is federally illegal, and SpaceX has a federal contract. “
As a result, Musk found himself subject to a series of drug tests.
“After that I had to do random drug tests and stuff to prove that I wasn’t like a drug addict… They did all the drug tests on me and randomly… I had one Random drug testing throughout the year,” he explained.
In the United States, the trajectory of marijuana legalization has made considerable progress at the state level. By the time Musk took the drug on Rogan’s podcast in 2018, marijuana had already been legalized in multiple states. On the federal front, however, cannabis remains at a standstill. — and remains — classified as a Schedule I substance under the Controlled Substances Act.
However, this status may soon change.
read more: This Pennsylvania trio spent $100,000 to buy an abandoned school and transform it into a 31-unit apartment building — How to invest in real estate without doing the heavy lifting
From Schedule One to Schedule Three?
The U.S. Food and Drug Administration (FDA) is recommending that marijuana be reclassified from a Schedule I substance to a Schedule III substance under the Controlled Substances Act, based on scientific and medical evaluation. The advice was recently released in a document released by the U.S. Department of Health and Wellness. Human services.
“After evaluating all available preclinical, clinical, and epidemiological data, the FDA recommends that cannabis be rescheduled from Schedule I to Schedule III of the CSA,” the document states.
“Schedule III drugs are classified as having less abuse potential than drugs or other substances in Schedules I and II, currently have accepted medical use in the United States, and may cause moderate or low degree of physical dependence or High degree of psychological dependence from their use. NIDA [National Institute on Drug Abuse] Agree with this suggestion. “
Transitioning from Schedule I to Schedule III would reposition cannabis from the same category as heroin and LSD to a category that includes anabolic steroids and substances like ketamine.
Although the DEA has not yet acted on this recommendation, it has the potential to usher in a new era for the cannabis industry.
The industry is reportedly already booming. Macroview ResearchAccording to statistics, the U.S. cannabis market is valued at $13.2 billion in 2022. Furthermore, this number is expected to continue rising at a compound annual growth rate of 14.2% from 2023 to 2030.
What to read next
This article provides information only and should not be considered advice. This article is provided without warranty of any kind.